There were 594 press releases posted in the last 24 hours and 150,042 in the last 365 days.

Ampio October 24th Investor Deadline: Bernstein Liebhard LLP Reminds Investors of the Important Upcoming Deadline in the Shareholder Class Action Lawsuit Against Ampio Pharmaceuticals, Inc. - AMPE

NEW YORK, Oct. 19, 2018 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the important October 24, 2018 lead plaintiff deadline in the shareholder class action lawsuit against Ampio Pharmaceuticals, Inc. (“Ampio” or the “Company”) (NYSE MKT: AMPE). The lawsuit seeks to recover damages on behalf of those who purchased the securities of Ampio between December 14, 2017 and August 7, 2018, both dates inclusive (the “Class Period”).

If you purchased Ampio securities, and/or would like to discuss your legal rights and options, please visit Ampio Shareholder Class Action Lawsuit or contact Daniel Sadeh toll free at (877) 779-1414 or

According to the lawsuit, throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) the FDA would find Ampio’s AP-003-C Phase 3 clinical trial inadequate and not well-controlled; (2) as a result, Ampio had not successfully completed two pivotal clinical trials for Ampion; (3) consequently, Defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

On August 7, 2018, during aftermarket hours, Ampio filed a Form 8-K with the SEC providing a regulatory update of the FDA’s review of Ampion, including the AP-003-A trial. Ampio stated that it “met with the FDA in July 2018 and have received a letter in response thereto.” In the letter, “the FDA stated that…that as a single trial the AP-003-A study alone does not appear to provide sufficient evidence of effectiveness to support a BLA…[and] the FDA does not consider the AP-003-C trial to be an adequate and well-controlled clinical trial.” Ampio stated that “[t]he FDA recommended that [it] perform an additional randomized trial with a concurrent control group and that [it] request a Special Protocol Assessment to obtain FDA concurrence of the trial design before beginning the study.”

On this news, Ampio stock fell $2.25 per share, or over 78%, from its previous closing price to close at $0.61 per share on August 8, 2018, damaging investors.

If you wish to serve as lead plaintiff, you must move the Court no later than October 24, 2018. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff. If you choose to take no action, you may remain an absent class member.

If you purchased Ampio securities, and/or would like to discuss your legal rights and options, please visit or contact Daniel Sadeh toll free at (877) 779-1414 or

Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of lawsuits and class actions, the Firm has been named to The National Law Journal’s “Plaintiffs’ Hot List” thirteen times and listed in The Legal 500 for ten consecutive years.

ATTORNEY ADVERTISING. © 2018 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. The lawyer responsible for this advertisement in the State of Connecticut is Michael S. Bigin.  Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information

Daniel Sadeh
Bernstein Liebhard LLP
(877) 779-1414

/EIN News/ --


Distribution channels: Technology

EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.